Relmada Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Leadership changes show if a company is bringing in experienced talent to guide its business strategy.
More authorized shares allow the company to raise money or pay employees, but can dilute existing shareholders.
Quarterly results show if a company is making progress toward its goals and managing money wisely.
Quarterly reports give detailed financial data and management updates required by the SEC.
Resale registrations mean existing investors can sell shares, which affects share prices and ownership.
Registration statements let companies raise money by selling stock or bonds to the public when needed.
Annual results show if a company achieved its yearly goals and financial health over twelve months.
Stocky reads Relmada Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Relmada Therapeutics, Inc.'s most recent tracked filing was a 8-K on 28 Jul 2026: Appoints Bipin Dalmia as Chief Business Officer.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.